ResearchIn-Press PreviewClinical ResearchImmunologyInfectious disease
Open Access |
10.1172/jci.insight.201111
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Izquierdo-Pujol, J. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Pedreño-Lopez, N. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Pidkova, T. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Nevot, M. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Urrea, V. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Laguía, F. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Muñoz-López, F. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Dalmau, J. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Gonzalez-Aumatell, A. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Carreras-Abad, C. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Méndez, M. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Rodrigo, C. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by
Massanella, M.
in:
PubMed
|
Google Scholar
|
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by
Blanco, J.
in:
PubMed
|
Google Scholar
|
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by
Carrillo, J.
in:
PubMed
|
Google Scholar
|
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by Trinité, B. in: PubMed | Google Scholar
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by
Martinez-Picado, J.
in:
PubMed
|
Google Scholar
|
1IrsiCaixa, Badalona, Spain
2Department of Pediatrics, Germans Trias i Pujol University Hospital, Badalona, Spain
Find articles by
Morón-López, S.
in:
PubMed
|
Google Scholar
|
Published February 19, 2026 - More info
The biological mechanisms underlying long COVID in the pediatric population are poorly understood. Our study aimed to characterize the immune pathophysiology of long COVID in children and young people (CYP). We analyzed major immune cell compartments in PBMCs, as well as specific SARS-CoV-2 antibody response in CYP with (n=99) and without (n=18) long COVID at three months following acute infection. Our findings indicate that pediatric long COVID is associated with a dysregulated immune response characterized by altered innate immunity and overactivated T-, B- and NK-cell responses. Furthermore, CYP with long COVID had an impaired humoral response to SARS-CoV-2 marked by a dysregulated B-cell compartment and lower levels of anti-RBD IgG and IgA. This correlated with reduced neutralizing capacity against SARS-CoV-2. Random forest analysis identified CCR6 expression on myeloid cells as the most relevant biomarker that distinguishes long COVID from control individuals with 79% accuracy.